← Every company
Amicus Therapeutics Inc Patents
What Amicus Therapeutics Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
FOLD on carbonthat →Filings on file
22
Granted
0
Still pending
22
Filed under
3 names
22 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| METHOD FOR SELECTION OF HIGH M6P RECOMBINANT PROTEINSA61K 38/00, C12N 9/2408, A61P 3/08, A61P 43/00, A61P 3/00, A61K 38/47, C07K 1/18, C07K 1/22, C07K 1/34, C12Y 302/0102Filed as Amicus Therapeutics, Inc.2026-06-17Hung V. Do | pending |
| High Concentration Alpha-Glucosidase Compositions For The Treatment Of Pompe DiseaseA61K 38/47, A61P 21/00, A61P 43/00, A61P 1/16, A61P 9/00, A61P 25/00, A61K 9/0019, A61K 31/445, A61K 31/7008, A61K 47/22, A61K2300/00, C12N 9/2408, C12N 9/96, C12Y 302/0102Filed as Amicus Therapeutics, Inc.2025-09-22Kenneth Valenzano | pending |
| METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING RENAL IMPAIRMENTA61K 31/445, A61P 13/12Filed as Amicus Therapeutics, Inc.2025-09-19Franklin Johnson | pending |
| Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA GeneA61K 31/445, A61P 43/00, A61P 3/00, A61K 9/0019, A61K 9/0053Filed as Amicus Therapeutics, Inc.2025-09-15Elfrida Benjamin | pending |
| Gene Therapy Constructs for the Treatment of Pompe DiseaseA61K 48/005, A61P 3/00, A01K2217/075, A01K2227/105, A01K2267/0306, A61K 9/0019, A61K 38/00, A61K 48/0075, A61K 48/0083, C07K 14/65, C07K2319/00, C07K2319/02, C12N 9/2402, C12N 9/2408, C12N 15/86, C12N2750/14143, C12Y 302/0102Filed as Amicus Therapeutics, Inc.2025-07-11Hung V. Do | pending |
| NITROSAMINE COMPOUNDS AND METHODS FOR ANALYZING THE SAMEFiled as AMICUS THERAPEUTICS, INC.2025-06-26MOHAMMED SHEIKH SHEIKH | pending |
| RECOMBINANT ALPHA-GALACTOSIDASE A PROTEINS AND GENE THERAPYFiled as AMICUS THERAPEUTICS, INC.2025-06-20TOBIAS WILLER | pending |
| METHODS FOR TREATING LATE ONSET POMPE DISEASE IN PEDIATRIC PATIENTSA61K 38/47, A61P 43/00, A61P 3/00, A61K 31/445, A61K 45/06, A61K2300/00, C12Y 302/0102Filed as Amicus Therapeutics, Inc.2025-06-02Jay Barth | pending |
| METHODS FOR TREATING INFANTILE-ONSET POMPE DISEASE IN PEDIATRIC PATIENTSA61K 38/47, A61P 21/00, A61P 43/00, A61P 3/00, A61K 31/445, A61K2300/00, C12Y 302/0102Filed as Amicus Therapeutics, Inc.2025-06-02Jay Barth | pending |
| Methods Of Treating Fabry Patients Having Renal ImpairmentA61K 31/445, A61P 43/00, A61P 3/00, A61P 9/00, A61P 13/12, A61K 9/48Filed as Amicus Therapeutics, Inc.2025-04-21Jeff Castelli | pending |
| HIGHLY PURIFIED BATCHES OF PHARMACEUTICAL GRADE 1-DEOXYGALACTONOJIRIMYCIN COMPOUNDSC07D 211/46, C07B2200/13Filed as Amicus Therapeutics, Inc.2025-04-11Kamlesh Sheth | pending |
| Highly Potent Acid Alpha-Glucosidase With Enhanced CarbohydratesC12N 9/2402, C12N 9/2465, A61P 3/08, A61P 43/00, A61K 9/19, A61K 38/47, A61K 47/26, A61K 48/005, C12N 15/09, C12N2510/02, C12Y 302/0102Filed as Amicus Therapeutics, Inc.2025-01-17Russell Gotschall | pending |
| Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe DiseaseA61K 38/47, A61P 21/00, A61P 43/00, A61P 3/00, A61K 9/0019, A61K 9/0053, A61K 31/445, A61K2300/00, C12N 9/2402, C12Y 302/0102Filed as Amicus Therapeutics, Inc.2025-01-17Hung V. Do | pending |
| Recombinant Human Acid Alpha-GlucosidaseA61P 21/00, A61K 38/47, A61P 43/00, A61P 25/00, C12Y 302/0102Filed as Amicus Therapeutics, Inc.2024-11-11Hung V. Do | pending |
| Methods for Treating Pompe DiseaseA61K 38/47, C12Y 302/0102, A61P 21/00, A61P 3/00, A61K 9/0019, A61K 47/02, A61K 47/12, A61K 47/38Filed as Amicus Therapeutics, Inc.2024-11-05Jay Barth | pending |
| METHODS OF TREATING FABRY DISEASE IN PATIENTS HAVING RENAL IMPAIRMENTFiled as Amicus Therapeutics, Inc.2024-09-19Franklin Johnson | pending |
| Disulfide Bond Stabilized Polypeptide Compositions And Methods Of UseA61K 48/0058, A61P 43/00, A61K 38/465, A61K 38/47, A61K 48/0033, C07H 21/04, C12N 15/79, C12N 15/86, C12N2750/14143, C12N2800/00, C12Y 301/02022, C12Y 302/01022, C12N 9/2465, A61P 3/00, A61K 38/00, A61K 48/005, C07K2319/35, C12N 9/2402, C12Y 302/01017Filed as Amicus Therapeutics, Inc.2024-08-19Hung V. Do | pending |
| Nitrosamine Compounds and Methods for Analyzing the SameFiled as Amicus Therapeutics, Inc.2024-06-26MOHAMMED OSMAN SHEIKH | pending |
| RECOMBINANT ALPHA-GALACTOSIDASE A PROTEINS AND GENE THERAPYFiled as Amicus Therapeutics, Inc.2024-06-20Tobias Willer | pending |
| Compositions And Methods For Treating Mucopolysaccharidosis IIIAC12N 9/14, A01K2217/075, A01K2227/105, A61K 38/00, A61K 48/00, C07K 14/65, C07K2319/02, C07K2319/06, C07K2319/50, C12N 15/86, C12N2750/14143, C12Y 310/01001Filed as Amicus Therapeutics, Inc2024-05-10Leida Rassouli-Taylor | pending |
| GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF POMPE DISEASEFiled as AMICUS THERAPEUTICS, INC.2024-01-12HUNG V. DO | pending |
| Methods of Treating Fabry Disease in Pediatric PatientsA61K 31/445, A61P 3/00Filed as Amicus Therapeutics, Inc.2024-01-11Franklin Johnson | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.